XPrecise

XPrecise, based in Beijing, China, specializes in advanced medical diagnostic solutions aimed at enhancing precision medicine and personalized healthcare through innovative technologies. Founded in 2022, XPrecise operates from its headquarters in Beijing, China, focusing on developing cutting-edge diagnostic tools to improve patient care. The company has engaged in a single deal to date, with their most recent deal occurring on December 29, 2025, signaling their growing presence in the medical diagnostics sector. XPrecise-Med specializes in advanced medical diagnostic solutions, with a core focus on precision medicine and personalized healthcare.

Their flagship products include a suite of diagnostic tools that utilize state-of-the-art technologies to deliver accurate and timely health assessments. These tools are designed to enhance patient outcomes by enabling healthcare providers to tailor treatment plans based on individual patient profiles. The company serves a diverse client base, including hospitals, clinics, and research institutions, primarily in North America and select markets in Europe and Asia. Through these products, XPrecise-Med aims to address critical healthcare challenges such as disease prevention, early diagnosis, and effective treatment monitoring, thus improving overall healthcare delivery.

The revenue model of XPrecise-Med is primarily structured around the sale of diagnostic products and associated services to healthcare providers. Transactions typically occur through direct sales to hospitals and clinics, establishing long-term partnerships that facilitate ongoing product usage and support. Clients may engage with XPrecise-Med under a subscription model for software updates and continued access to their diagnostic platforms. The pricing structure for their offerings is designed to provide value to healthcare providers while ensuring accessibility for a broad range of services.

Additionally, the company may derive revenue from licensing agreements related to proprietary diagnostic technologies, reinforcing its market position in precision medicine. In December 2025, XPrecise raised an undisclosed amount of Series A funding from new investor Launcher Capital. This round of financing will be used to increase investment in product research and development, promote market expansion, and improve its service system. The company is focused on designing and launching new diagnostic products that will further enhance its offerings, while actively pursuing expansion into North America and European markets by 2026.